VALIRX PLC

Board/Management Information • Nov 1, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9370R

ValiRx PLC

01 November 2013

1st November 2013

ValiRx Plc

("ValiRx" or the "Company")

Change of Broker

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics for personalised medicine, announces that Daniel Stewart & Company Plc has been appointed as sole broker to the Company with immediate effect.

- ENDS -

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka	www.ValiRx.com
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:+44 (0) 20 7148 7900
Liam Murray / Avi Robinson
Daniel Stewart & Company Plc (Broker)	Tel: +44 (0) 20 7776 6550
Paul Shackleton / Mark Treharne
Peckwater PR	Tel: +44 (0)7879 458 364
Tarquin Edwards	tarquin.edwards@peckwaterpr.co.uk

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1.   ValiFinn is the biomarkers and diagnostic development division

2.  ValiPharma is the therapeutics division with two embedded technologies primarily directed at the      treatment of cancers.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPBIBDGLUXBGXB